12th Aug 2019 07:00
Yourgene Health plc
("Yourgene" or the "Company")
Amendment to Share Options
Manchester, UK - 12 August 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces an amendment to existing share options held by certain Directors of the Company.
The existing share options below (issued 19 March 2014) have had their performance conditions modified so as to be aligned with other senior incentives:
Name | Existing options subject to amendment | Total number of options held |
Adam Reynolds | 591,666 | 591,666 |
Nick Mustoe | 591,666 | 591,666 |
The exercise price of these options has not been changed and remains at 10 pence.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact: |
| |||
Yourgene Health plc | Tel: +44 (0)161 667 1053 | |||
Lyn Rees, Chief Executive Officer |
| |||
Barry Hextall, Chief Financial Officer |
| |||
Joanne Cross, Head of Marketing |
| |||
| ||||
|
| |||
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0)20 7213 0880 | |||
Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
|
| |||
Stifel Nicolaus Europe Limited (Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
Nicholas Moore / Matthew Blawat / Ben Maddison |
| |||
|
| |||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] | |||
Paul McManus / Lianne Cawthorne / Anna Dunphy | Mob: 07980 541 893 / 07584 391 303 / | |||
| 07876 741 001 | |||
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Related Shares:
YGEN.L